nirsevimab

FDA starts review of Sanofi, AZ antibody for RSV prevention
FDA starts review of Sanofi, AZ antibody for RSV prevention
Pharmaphorum
RSV
Sanofi
AstraZeneca
FDA
antibodies
nirsevimab
Flag link:
Sanofi, AstraZeneca clinch first OK for RSV antibody — just as vaccines line up at regulators
Sanofi, AstraZeneca clinch first OK for RSV antibody — just as vaccines line up at regulators
Endpoints
Sanofi
AstraZeneca
RSV
nirsevimab
Europe
vaccines
Flag link:
Sanofi, AZ's blockbuster hopeful RSV med nears first approval as showdown with Pfizer, GSK looms
Sanofi, AZ's blockbuster hopeful RSV med nears first approval as showdown with Pfizer, GSK looms
Fierce Pharma
Sanofi
AstraZeneca
Pfizer
GSK
nirsevimab
Beyfortus
RSV
Flag link:
AZ, Sanofi build case for one-shot RSV antibody
AZ, Sanofi build case for one-shot RSV antibody
Pharmaforum
AstraZeneca
Sanofi
RSV
nirsevimab
Flag link:
Sanofi, AstraZeneca Express Optimism Over Phase III Infant RSV Results
Sanofi, AstraZeneca Express Optimism Over Phase III Infant RSV Results
BioSpace
Sanofi
AstraZeneca
nirsevimab
vaccines
RSV
clinical trials
Flag link:
Sanofi, AstraZeneca mark big leap toward filing of RSV drug in 2022, with safety data in hand to challenge Synagis
Sanofi, AstraZeneca mark big leap toward filing of RSV drug in 2022, with safety data in hand to challenge Synagis
Endpoints
Sanofi
AstraZeneca
RSV
clinical trials
nirsevimab
Synagis
Flag link:
AstraZeneca and Sanofi Announce Big Breakthrough With RSV Vaccine
AstraZeneca and Sanofi Announce Big Breakthrough With RSV Vaccine
BioSpace
AstraZeneca
Sanofi
vaccines
RSV
nirsevimab
clinical trials
Flag link: